[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20230855A1 - Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos - Google Patents

Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos

Info

Publication number
PE20230855A1
PE20230855A1 PE2023000248A PE2023000248A PE20230855A1 PE 20230855 A1 PE20230855 A1 PE 20230855A1 PE 2023000248 A PE2023000248 A PE 2023000248A PE 2023000248 A PE2023000248 A PE 2023000248A PE 20230855 A1 PE20230855 A1 PE 20230855A1
Authority
PE
Peru
Prior art keywords
heteroaryl
derivatives
alkyl
pharmaceutical uses
substituted spiropiperidinyl
Prior art date
Application number
PE2023000248A
Other languages
English (en)
Inventor
Mallesh Bushaboina
Xin Chen
Atwood Kim Cheung
Andrew James Culshaw
Timothy Brian Hurley
Nancy Labbe-Giguere
Wolfgang Miltz
David Orain
Tajesh Patel
Srinivasan Rajagopalan
Till Roehn
David Andrew Sandham
Gebhard Thoma
Ritesh Bhanudasji Tichkule
Rudolf Walchli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20230855A1 publication Critical patent/PE20230855A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Referida a un compuesto de la Formula (I), en donde R1 es fenilo opcionalmente sustituido con uno o mas sustituyentes halogeno; R2 es H o fluoro; X1 es CH2 u O; R4 es un heteroarilo mono o biciclico, opcionalmente sustituido con uno o mas sustituyentes R3; R3 es arilo C6-10, bencilo, alquilo C1-6, cicloalcoxi C3-7, hidroxialquilo C1-6, alcoxi C1-6 alquilo C1-6, halo, haloalquilo C1-6, entre otros. Dichos compuestos son inhibidores de la leucotrieno C4 sintasa (LTC4S).
PE2023000248A 2020-08-14 2021-08-12 Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos PE20230855A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20191191 2020-08-14
PCT/IB2021/057427 WO2022034529A1 (en) 2020-08-14 2021-08-12 Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
PE20230855A1 true PE20230855A1 (es) 2023-05-29

Family

ID=72088005

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000248A PE20230855A1 (es) 2020-08-14 2021-08-12 Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos

Country Status (21)

Country Link
US (2) US11708366B2 (es)
EP (1) EP4196478A1 (es)
JP (2) JP7545570B2 (es)
KR (1) KR20230051227A (es)
CN (1) CN116157404A (es)
AR (1) AR123241A1 (es)
AU (2) AU2021325431B2 (es)
BR (1) BR112023002031A2 (es)
CA (1) CA3185469A1 (es)
CL (1) CL2023000418A1 (es)
CO (1) CO2023002940A2 (es)
CR (1) CR20230125A (es)
DO (1) DOP2023000028A (es)
EC (1) ECSP23017158A (es)
IL (1) IL299091A (es)
MX (1) MX2023001725A (es)
PE (1) PE20230855A1 (es)
SA (1) SA523442503B1 (es)
TW (1) TW202220990A (es)
UY (1) UY39377A (es)
WO (1) WO2022034529A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7545570B2 (ja) * 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998834A (en) 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2003028732A1 (fr) 2001-09-28 2003-04-10 Kyowa Hakko Kogyo Co., Ltd. Antagoniste de recepteur
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
AU2008294535A1 (en) 2007-09-04 2009-03-12 Biolipox Ab BIS-aromatic compounds useful in the treatment of inflammation
ES2459496T3 (es) 2009-12-21 2014-05-09 Novartis Ag Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
EP2545036A1 (en) 2010-03-12 2013-01-16 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
US20120101110A1 (en) 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
KR101893756B1 (ko) 2011-03-14 2018-09-03 베링거 인겔하임 인터내셔날 게엠베하 류코트리엔 생성의 벤조디옥산 억제제
CN103814016B (zh) 2011-06-10 2017-03-08 默克专利有限公司 生产具有btk抑制活性的嘧啶和吡啶化合物的组合物和方法
WO2013012844A1 (en) 2011-07-19 2013-01-24 Boehringer Ingelheim International Gmbh Arylpyrazole ethers as inhibitors of leukotriene a4 hydrolase
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
WO2013081016A1 (ja) 2011-11-29 2013-06-06 小野薬品工業株式会社 プリノン誘導体塩酸塩
AR091315A1 (es) 2012-03-06 2015-01-28 Boehringer Ingelheim Int Inhibidores de benzodioxano de la produccion de leucotrieno
TW201350475A (zh) 2012-03-06 2013-12-16 Boehringer Ingelheim Int 用於組合療法之白三烯素生成之苯并二噁烷抑制劑
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
AR091786A1 (es) 2012-07-17 2015-02-25 Boehringer Ingelheim Int Inhibidores de la produccion de leucotrienos
PT3181567T (pt) 2012-09-10 2019-06-24 Principia Biopharma Inc Compostos de pirazolopirimidina como inibidores de cinase
EP2951179B1 (en) 2013-02-04 2020-03-11 Merck Patent GmbH Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EP2968359B1 (en) 2013-03-12 2021-01-20 Celltaxis, LLC Methods of inhibiting leukotriene a4 hydrolase
MX2015011676A (es) 2013-03-14 2016-04-25 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
AU2014239567B2 (en) 2013-03-14 2017-12-14 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
KR101793807B1 (ko) 2013-04-25 2017-11-03 베이진 엘티디 단백질 키나제 억제제로서의 융합된 헤테로시클릭 화합물
EP3022194B1 (en) 2013-07-15 2017-05-17 Boehringer Ingelheim International GmbH Inhibitors of leukotriene production
WO2015009609A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
KR20160093062A (ko) 2013-12-05 2016-08-05 아세르타 파마. 비.브이. Pi3k 억제제 및 btk 억제제의 치료적 조합
PL3083564T3 (pl) 2013-12-20 2018-12-31 Novartis Ag Pochodne kwasu heteroarylobutanowego jako inhibitory LTA4H
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
SG10201903578VA (en) 2014-10-24 2019-05-30 Bristol Myers Squibb Co Indole carboxamides compounds useful as kinase inhibitors
AU2015341913B2 (en) 2014-11-03 2020-07-16 Iomet Pharma Ltd Pharmaceutical compound
EP3221315A1 (en) 2014-11-21 2017-09-27 Laboratorios Del. Dr. Esteve, S.A. 1,9-diazaspiro undecane compounds having multimodal activity against pain
MX2017008386A (es) 2014-12-24 2018-03-23 Principia Biopharma Inc Administración específica del sitio de un inhibidor de btk.
GB201507753D0 (en) * 2015-05-06 2015-06-17 Biolipox Ab New compounds and uses
PE20180521A1 (es) 2015-06-03 2018-03-14 Principia Biopharma Inc Inhibidores de tirosina-cinasas
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
JP6889494B2 (ja) 2015-10-09 2021-06-18 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
EP4014977A1 (en) 2015-11-04 2022-06-22 Merck Patent GmbH Pyrimidine compounds with btk inhibitory activity for use in treating cancer
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
KR102688907B1 (ko) 2016-01-05 2024-07-29 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Btk 키나아제 억제제의 결정질 형태 및 이의 제조 방법
CN109600989B (zh) 2016-06-29 2022-11-04 普林斯匹亚生物制药公司 2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁烷-3-基)哌嗪-1-基]戊-2-烯腈的改性的释放制剂
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
JP7545570B2 (ja) * 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用

Also Published As

Publication number Publication date
TW202220990A (zh) 2022-06-01
JP7545570B2 (ja) 2024-09-04
AU2024200054A1 (en) 2024-01-25
CL2023000418A1 (es) 2023-09-29
JP2024123025A (ja) 2024-09-10
AU2021325431A1 (en) 2023-01-19
IL299091A (en) 2023-02-01
AR123241A1 (es) 2022-11-09
US20220048909A1 (en) 2022-02-17
CA3185469A1 (en) 2022-02-17
US20240043425A1 (en) 2024-02-08
MX2023001725A (es) 2023-02-22
SA523442503B1 (ar) 2024-07-31
DOP2023000028A (es) 2023-03-15
WO2022034529A1 (en) 2022-02-17
JP2023537357A (ja) 2023-08-31
CO2023002940A2 (es) 2023-03-17
ECSP23017158A (es) 2023-04-28
KR20230051227A (ko) 2023-04-17
US11708366B2 (en) 2023-07-25
EP4196478A1 (en) 2023-06-21
BR112023002031A2 (pt) 2023-03-07
UY39377A (es) 2022-03-31
AU2021325431B2 (en) 2024-01-18
CR20230125A (es) 2023-05-11
CN116157404A (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
PE20230855A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
PE20230825A1 (es) Inhibidores de kras triciclicos fusionados
RS53142B (en) UNITS THAT HAVE ANTAGONISTIC ACTIVITY ON CRTH2
AR061243A1 (es) Derivados de n-2-feniletil-carboxamidas, composiciones para el control de mocroorganismos fitopatogenicos que los comprenden y un metodo de control o prevencion de infestacion de plantas utiles que los emplea.
PE20121431A1 (es) Derivados de pirimidina como inhbidores de la enzima cinasa ptk2
CO5611139A2 (es) Pirimidinas aril sustituidas y el uso de las mismas
PE20220808A1 (es) Derivados de benzisoxazol sulfonamida
EA201170096A1 (ru) Замещенные производные пиримидона
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
EA202190657A1 (ru) Ингибиторы саркомера сердца
AR083180A1 (es) Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
CO6270309A2 (es) Inhibidores tetrahidropiranocromeno de gamma secretasa
RS54369B1 (en) NEW QUINOLINE COMPOUNDS SUBSTITUTED AS S-NITROSOGLUTATHION REDUCTASE INHIBITORS
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
PE20211388A1 (es) Compuestos
RU2008102993A (ru) НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
AR125998A1 (es) Derivados de tetrahidroisoquinolina microbiocida
EA202191968A1 (ru) Новые замещенные производные сульфонилмочевины
ES2721280T3 (es) Nuevos inhibidores de la FYN quinasa
CY1116388T1 (el) 5-(φαινυλο/πυριδινυλο-αιθινυλο)-2-πυριδινο/2-πυριμιδινο-καρβοξαμιδια ως mglur5 ρυθμιστες
EA202190462A1 (ru) Индольные и азаиндольные ингибиторы ферментов pad